Evidence map›Paper›PMID 33373380›Full record

ArticlePloS one2020

Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study.

Richard Muwonge, Partha Basu, Tarik Gheit, Devasena Anantharaman, Yogesh Verma, Neerja Bhatla, Smita Joshi, Pulikottil O Esmy, Usha Rani Reddy Poli, Anand Shah and 22 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00923702 (Randomised Trial of Two Versus Three Doses of Human Papillomavirus), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00923702 phase4unknown statusnot on this map

Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

TypeinterventionalSponsorPartha BasuRan2009 to 2026Enrolled22,729ConditionsCervical Cancer, Cervical Precancerous LesionsArmsProphylactic quadrivalent HPV vaccine Merck (Gardasil®)
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Richard MuwongeScreening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
Partha BasuScreening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-0124-4050
Tarik GheitInfections and Cancer Biology Group, Section of Infections, International Agency for Research on Cancer, Lyon, France.
Devasena AnantharamanRajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
Yogesh VermaSikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok, Sikkim, India.
Neerja BhatlaDepartment of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
Smita JoshiJehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
Pulikottil O EsmyChristian Fellowship Community Health Centre, Ambillikai (near Oddanchathram), Dindigul District, Tamil Nadu, India.
Usha Rani Reddy PoliIndian Institution of Public Health-Hyderabad, Public Health Foundation of India, Hyderabad, India.ORCID 0000-0002-6336-2274
Anand ShahGujarat Cancer & Research Institute (GCRI), M.P. Shah Cancer Hospital, Civil Hospital Campus, Asarwa, Ahmedabad, India.
Eric ZomawiaCivil Hospital, Aizawl, Mizoram, India.
Surendra S ShastriDepartment of Health Disparities Research, Division of Cancer Prevention and Population Sciences, University of Texas M.D. Anderson Cancer Centre, Houston, TX, United States of America.
Sharmila PimpleDepartment of Preventive Oncology, Tata Memorial Center, Tata Memorial Hospital & Cancer Research Inst, Parel, Mumbai, India.
Priya R PrabhuRajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
Sanjay HingmireTata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi District Solapur, Maharashtra, India.
Aruna ChiwateTata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi District Solapur, Maharashtra, India.
Catherine SauvagetScreening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
Eric LucasScreening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
Sylla G MalviTata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi District Solapur, Maharashtra, India.
Maqsood SiddiqiCancer Foundation of India, Kolkata, West Bengal, India.
Subha SankaranRajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
Thiraviam Pillai Rameshwari Ammal KannanRajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
Rintu VargheseRajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
Uma DivateJehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
Shachi VashistDepartment of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
Gauravi MishraDepartment of Preventive Oncology, Tata Memorial Center, Tata Memorial Hospital & Cancer Research Inst, Parel, Mumbai, India.
Radhika JadhavJehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
Massimo TommasinoInfections and Cancer Biology Group, Section of Infections, International Agency for Research on Cancer, Lyon, France.
M Radhakrishna PillaiRajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
Rengaswamy SankaranarayananResearch Triangle Institute (RTI) International India, New Delhi, India.
Kasturi JayantResearch Triangle Institute (RTI) International India, New Delhi, India.
Indian HPV vaccine study group

Funding

World Health Organization 001
6 · The paper itself

Abstract

In context of the ongoing multi-centric HPV vaccine study in India, unvaccinated married women (N = 1484) aged 18-23 years were recruited in 2012-2015 as age-matched controls to the vaccinated women and followed up yearly. We assess type-specific prevalence, natural history and potential determinants of human papillomavirus (HPV) infection in these unvaccinated women. Cervical samples were collected yearly for at least four consecutive years. A Multiplex Type-Specific E7-Based polymerase chain reaction assay was used to detect 21 HPV types. HPV prevalence was 36.4% during 6 years. Most common HPV types were 16 (6.5%) and 31 (6.1%). Highest persistence were observed for HPV 35 (62.5%) and 52 (25%). New HPV acquisition rate was 5.6/1000 person-months of observation (PMO), highest for HPV 16 (1.1/1000 PMO). Type-specific clearance rates ranged between 2.9-5.5/100 PMO. HPV 16 and/or 18 infections were 41% (95% CI 4-63%) lower among women with 2-<3 years between marriage and first cervical sample collection compared to those with <2 years. HPV prevalence and acquisition rates in young Indian women were lower than their Western counterparts. HPV 16 infections being most common shows the importance and potential impact of HPV vaccination in India. Women with 2-3 years exposure had reduced risk possibly due to higher infections clearance.

Indexed as

Sexual BehaviorAdolescentAdultFemaleHumansIndiaLongitudinal StudiesPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesPrevalenceVaccinationYoung AdultPapillomavirus Vaccines

Identifiers

PMID33373380
PMCPMC7771682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.